Publications by authors named "E Verner"
To help guide treatment decisions and clinical trial matching, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy, a complementary approach to tissue testing, can assess tumor-specific DNA alterations circulating in the blood. Labcorp Plasma Complete is a next-generation sequencing, cell-free DNA comprehensive genomic profiling test that identifies clinically relevant somatic variants across 521 genes in advanced and metastatic solid cancers.
View Article and Find Full Text PDFJCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFArticle Synopsis
- The NHL29 trial evaluated the effectiveness of combining ibrutinib with R-mini-CHOP chemotherapy in patients over 75 with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- Results showed a 2-year overall survival rate of 68% and a progression-free survival rate of 60%, with an overall response rate of 76%.
- Despite some serious adverse events, including infections and diarrhea, improvements in health-related quality of life were noted among responders, indicating the treatment's viability for elderly patients.
Article Synopsis
- There is a growing interest in using historical patient data as synthetic controls for evaluating new drugs, but real-world outcomes often don't match those from clinical trials due to a lack of detailed cancer treatment data.
- The Australasian Leukaemia and Lymphoma Group's National Blood Cancer Registry (ALLG NBCR) provides comprehensive information on various factors influencing treatment outcomes, allowing for a comparison of 942 AML patients to clinical trial data for five specific drugs.
- The analysis reveals significant differences in treatment approaches and outcomes between real-world patients and clinical trial participants, indicating that while some results may align, discrepancies must be considered for accurately assessing the effectiveness of new therapies across different populations.
Introduction: Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor's molecular landscape. However, further evaluation of technical aspects related to the detection of gene rearrangements and copy number alterations is warranted.
Methods: There were 12 rearrangement-positive tumor specimens from patients with non-small cell lung cancer (NSCLC) previously detected via fluorescence hybridization (FISH), immunohistochemistry (IHC), and an RNA-based NGS assay, and 26 high gene copy number (GCN) cases detected by FISH, selected for this retrospective study.